ACT Genomics

About

ACT Genomics is a cancer molecular information service company teamed up with experts with multiple years’ experience in oncology

Taipei,T'ai-pei,Taiwan
101 - 250
http://www.actgenomics.com/

Highlights

Details

Last Funding Type: Series Unknown
Industries: Bioinformatics,Biotechnology,Genetics,Health Care,Information Technology
Founded date: Jan 1, 2014
Number Of Employee: 101 - 250
Operating Status: Active

ACT Genomics is a cancer molecular information service company teamed up with experts with multiple years’ experience in oncology, cancer genomics, and bioinformatics. The company’s technology provides the possibility to transform cancer genomic information into precision diagnosis and personalized treatments.

Every patient’s cancer is unique at the molecular level. Specific genetic alterations drive the pathogenesis and determine the treatment response of individual tumor. Understanding the genetic alteration helps to design a more effective treatment strategy and provide a more accurate prediction for patient’s outcome. The use of genomics is changing the paradigm of oncology treatment decisions and making great impacts on personalized treatment. Such comprehensive tumor profiling is now affordable due to rapid progress in sequencing and informatics technologies.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$20.50M

ACT Genomics has raised a total of $20.50M in funding over 2 rounds. Their latest funding was raised on Sep 6, 2020 from a Series Unknown round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 6, 2020	Series Unknown	—	3	—	—	Detail
Sep 26, 2018	Series C	—	1	CLSA Capital Partners	—	Detail
May 5, 2016	Series B	$12.50M	1	CDIB Capital	—	Detail
Feb 13, 2015	Series A	$8M	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

5

ACT Genomics is funded by 5 investors. CLSA Capital Partners and CDIB Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
CLSA Capital Partners	Yes	Series C
CDIB Capital	Yes	Series B
Hong Kong Science and Technology Parks Corporation (HKSTP)	—	Series Unknown
Aflac Global Ventures	—	Series Unknown
Kyoto University Innovation Capital	—	Series Unknown